Nestlé partners with Helaina on bioactive proteins for infant nutrition

Nestlé is putting Helaina’s effera human lactoferrin into its early-life nutrition pipeline through a multi-year strategic innovation collaboration, a sign that bioactive proteins are getting closer to mainstream infant nutrition without yet being simple acquisition targets. The deal centers on new proteins for early-life nutrition and infant formula, pairing Nestlé’s product-development reach with Helaina’s precision fermentation platform and biotech know-how.

Effera, launched in 2024, sits at the heart of that push. Helaina describes the ingredient as a human-identical lactoferrin and says it is designed to support iron balance, immune function and gut health. That matters in infant nutrition because lactoferrin is not just another source of protein grams. It is an iron-binding glycoprotein tied to intestinal health, immune support and microbiota effects, which gives it a functional story that goes beyond nutrition labels and into biology.

The collaboration also shows why Nestlé is choosing partnership over buying control. Early-life ingredients face a tougher path than standard proteins because they have to prove a biological effect, scale reliably and fit a highly scrutinized regulatory environment. Nestlé has spent years working on that proof problem itself. ClinicalTrials.gov shows a Nestlé-sponsored infant formula study using whey isolate enriched with lactoferrin that was completed and last updated in 2013. The Nestlé Nutrition Institute has also pointed to the ELFIN trial, which enrolled 2,203 infants and did not show significant reductions in late-onset sepsis or necrotizing enterocolitis. The message is clear: lactoferrin is promising, but the category still demands product-specific validation.

That is where collaboration becomes the business model. Isabelle Bureau-Franz said Nestlé has long been active in advancing scientific understanding of nutrients and bioactives important during early life, especially their interaction with the gut microbiome and immune system. She also said outside partnerships are central to the company’s innovation strategy because they open access to emerging technologies while deepening scientific knowledge. Nestlé reinforced that approach in 2024 with an Open Innovation Challenge focused on women’s physical and mental health and by saying it was building biotechnology capabilities to deliver ingredients with clinically proven bio-efficacy across the lifespan.

For Helaina, the Nestlé deal adds another validation point to a company founded in 2019 by food scientist Laura Katz. Helaina raised $45 million in Series B funding in September 2024, bringing total equity funding to $83 million, and said it would use the money to scale effera. The company has also described uses beyond infant nutrition, including women’s health, active nutrition, healthy aging, gut health, hair care and skin care.

Taken together, the deal suggests bioactive proteins are moving from startup promise into platform ingredients with more than one commercial life. Infant nutrition may be the proving ground, but Nestlé and Helaina are already building for the broader market that could follow.